Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain

Author: Benzinga Newsdesk | October 06, 2025 08:05am

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.

 

• European Society of Gene and Cell Therapy (ESGCT) Congress
  
  Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
  
  Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET  
  
  Session Title: 9A: Gene Editing II, Ex Vivo Applications
  
  Room: Parallel A
  
  Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine 
  
  Final Abstract Number: OR069

Abstracts are available to registrants on the ESGCT website. The oral presentation will also be posted to the "Posters & Presentations" section of the Company's website at the time of the presentation and will remain accessible following the event.

Posted In: EDIT